Three-Year Real-World LEQEMBI Data Presented at CTAD 2026
The LEQEMBI LEADER study analysis includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe Alzheimer’s disease, subcutaneous maintenance experience and sex-based outcomes.